MX2024005220A - Endoxifeno para el tratamiento del cancer. - Google Patents

Endoxifeno para el tratamiento del cancer.

Info

Publication number
MX2024005220A
MX2024005220A MX2024005220A MX2024005220A MX2024005220A MX 2024005220 A MX2024005220 A MX 2024005220A MX 2024005220 A MX2024005220 A MX 2024005220A MX 2024005220 A MX2024005220 A MX 2024005220A MX 2024005220 A MX2024005220 A MX 2024005220A
Authority
MX
Mexico
Prior art keywords
cancers
cancer
endoxifen
compositions
treatment
Prior art date
Application number
MX2024005220A
Other languages
English (en)
Spanish (es)
Inventor
Steven C Quay
Carla Grandori
Katannya Kapeli
Original Assignee
Atossa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atossa Therapeutics Inc filed Critical Atossa Therapeutics Inc
Publication of MX2024005220A publication Critical patent/MX2024005220A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024005220A 2021-10-28 2022-10-27 Endoxifeno para el tratamiento del cancer. MX2024005220A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163272869P 2021-10-28 2021-10-28
PCT/US2022/048061 WO2023076496A1 (en) 2021-10-28 2022-10-27 Endoxifen for treatment of cancers

Publications (1)

Publication Number Publication Date
MX2024005220A true MX2024005220A (es) 2024-05-16

Family

ID=86158538

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005220A MX2024005220A (es) 2021-10-28 2022-10-27 Endoxifeno para el tratamiento del cancer.

Country Status (10)

Country Link
US (1) US20250041245A1 (enExample)
EP (1) EP4422608A4 (enExample)
JP (1) JP2024541900A (enExample)
KR (1) KR20240093500A (enExample)
CN (1) CN118159259A (enExample)
AU (1) AU2022378576A1 (enExample)
CA (1) CA3232972A1 (enExample)
IL (1) IL312037A (enExample)
MX (1) MX2024005220A (enExample)
WO (1) WO2023076496A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022232924A1 (en) * 2021-03-11 2023-07-06 Atossa Therapeutics, Inc. Endoxifen for treatment of ovarian cancer
CN117338780A (zh) * 2023-09-21 2024-01-05 中国人民解放军海军军医大学 帕罗西汀在制备抗肿瘤药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033430A1 (en) * 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
EP2773340B1 (en) * 2011-11-04 2020-01-08 Myron R. Szewczuk Use of neu1 sialidase inhibitors in the treatment of cancer
DE102015222031A1 (de) * 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
WO2017127442A1 (en) * 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors
JP7662204B2 (ja) * 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
CN115087466A (zh) * 2019-12-12 2022-09-20 森迪生物科学公司 用于细胞的调控装甲的方法和组合物
AU2022232924A1 (en) * 2021-03-11 2023-07-06 Atossa Therapeutics, Inc. Endoxifen for treatment of ovarian cancer
CN119300811A (zh) * 2022-04-26 2025-01-10 阿托萨治疗学公司 高剂量因多昔芬制剂和使用方法

Also Published As

Publication number Publication date
WO2023076496A1 (en) 2023-05-04
EP4422608A4 (en) 2025-09-24
US20250041245A1 (en) 2025-02-06
EP4422608A1 (en) 2024-09-04
CA3232972A1 (en) 2023-05-04
JP2024541900A (ja) 2024-11-13
KR20240093500A (ko) 2024-06-24
IL312037A (en) 2024-06-01
CN118159259A (zh) 2024-06-07
AU2022378576A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
SG10201902664RA (en) Combination therapy for treating cancer
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
PH12016502354A1 (en) Pharmaceutical composition
MX420412B (es) Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr.
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
ZA202304965B (en) Combination therapy for treating cancer
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
JOP20200242A1 (ar) مركبات البلاديينوليد واستخداماتها
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020001727A (es) Terapia de combinacion.
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
JOP20200124A1 (ar) طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
EA201892631A1 (ru) Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
EA202193276A1 (ru) Способы лечения холангиокарциномы